Changes in the prevalence, treatment and control of hypertension in Germany? : a clinical-epidemiological study of 50.000 primary care patients by Labeit, Alexander Michael et al.
Changes in the Prevalence, Treatment and Control of
Hypertension in Germany? A Clinical-Epidemiological
Study of 50.000 Primary Care Patients
Alexander Michael Labeit
1,2*, Jens Klotsche
3, Lars Pieper
3, David Pittrow
3, Franziska Einsle
3,G u ¨nter
Karl Stalla
4, Hendrik Lehnert
5, Sigmund Silber
6, Andreas Michael Zeiher
7, Winfried Ma ¨rz
8,9,10,
Martin Wehling
1, Hans-Ulrich Wittchen
3
1Clinical Pharmacology Mannheim, Institute of Experimental and Clinical Pharmacology and Toxicology, Medical Faculty Mannheim of the University of Heidelberg,
Heidelberg, Germany, 2Department of Health Sciences, University of Leicester, Leicester, United Kingdom, 3Institute of Clinical Psychology and Psychotherapy and
Center of Clinical Epidemiology and Longitudinal Studies, TU Dresden, Dresden, Germany, 4Max Planck Institute of Psychiatry, Munich, Germany, 5Department of Internal
Medicine I, University of Lu ¨beck, Lu ¨beck, Germany, 6Private Cardiology Practice and Clinic, Munich, Germany, 7Department of Internal Medicine III, Cardiology, Goethe-
University Frankfurt, Frankfurt, Germany, 8Synlab Academy, Synlab Services GmbH, Mannheim, Germany, 9Mannheim Institute of Public Health, Rupertus Carola
University of Heidelberg, Medical Faculty Mannheim, Mannheim, Germany, 10Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of
Graz, Graz, Austria
Abstract
Introduction: Medical societies have developed guidelines for the detection, treatment and control of hypertension (HTN).
Our analysis assessed the extent to which such guidelines were implemented in Germany in 2003 and 2001.
Methods: Using standardized clinical diagnostic and treatment appraisal forms, blood pressure levels and patient
questionnaires for 55,518 participants from the cross-sectional Targets and Essential Data for Commitment of Treatment
(DETECT) study (2003) were analyzed. Physician’s diagnosis of hypertension (HTNdoc) was defined as coding hypertension in
the clinical appraisal questionnaire. Alternative definitions used were physician’s diagnosis or the patient’s self-reported
diagnosis of hypertension (HTNdoc,pat), physician’s or patient’s self-reported diagnosis or a BP measurement with a systolic
BP$140 mmHg and/or a diastolic BP$90 (HTNdoc,pat,bp) and diagnosis according to the National Health and Nutrition
Examination Survey (HTNNHANES). The results were compared with the similar German HYDRA study to examine whether
changes had occurred in diagnosis, treatment and adequate blood pressure control (BP below 140/90 mmHg) since 2001.
Factors associated with pharmacotherapy and control were determined.
Results: The overall prevalence rate for hypertension was 35.5% according to HTNdoc and 56.0% according to NHANES
criteria. Among those defined by NHANES criteria, treatment and control rates were 56.0% and 20.3% in 2003, and these
rates had improved from 55.3% and 18.0% in 2001. Significant predictors of receiving antihypertensive medication were:
increasing age, female sex, obesity, previous myocardial infarction and the prevalence of comorbid conditions such as
coronary heart disease (CHD), hyperlipidemia and diabetes mellitus (DM). Significant positive predictors of adequate blood
pressure control were CHD and antihypertensive medication. Inadequate control was associated with increasing age, male
sex and obesity.
Conclusions: Rates of treated and controlled hypertension according to NHANES criteria in DETECT remained low between
2001 and 2003, although there was some minor improvement.
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Hypertension (HTN) is a common cause for patient contacts
with primary physicians, and there is evidence of suboptimal
treatment and inadequate blood pressure control [1]. In Germany
the control status of hypertensive patients in the community [2]
and in primary care [3] has been repeatedly and consistently
found to be lower in comparison with other European countries
and the USA [4,5]. Prompted by these data and because of the
medical consequences and economic impact of hypertension,
considerable national and international activities targeting im-
proved recognition, treatment and control have been initiated
[6,7]. Against this background, re-examination of the recorded
prevalence and control of hypertension is essential to monitor
changes that might have occurred as a result of enhanced
prevention and treatment activities. Furthermore, a focus on
primary care is appropriate, because of the essential role of
primary care physicians as gatekeepers for hypertension manage-
ment in the German health care system [8].
Patients with hypertension alone have an increased risk for
cardiovascular morbidity and mortality [9] and hypertensive
patients with DM and/or metabolic syndrome as comorbidities
have even an increased risk for cardiovascular morbidity and
mortality compared to patients with hypertension alone [10,11]. It
has been shown by meta-analyses and different large-scale studies
that strict control of risk factors including cardiovascular disease,
DM, hyperlipidemia and smoking status in patients with
hypertension can effectively reduce cardiovascular mortality
among patients with hypertension [12]. A meta-analysis showed
that type-2 diabetic patients might benefit more from lower blood
pressure goals than non-diabetic patients with hypertension [13].
Consequently, national and international medical societies have
developed clear recommendations and guidelines for hypertension
and risk factor management and respective therapeutic targets
[14]. For example, the Seventh Report of the Joint National
Commission on Prevention, Detection, Evaluation and Treatment
of High blood pressure guidelines (JNC-7) recommend blood
pressure targets with systolic blood pressure levels below
140 mmHg and diastolic blood pressure levels below 90 mmHg,
while for patients with comorbidities the blood pressure (BP)
recommendation has been set at 130/80 mmHg [12]. In
hypertensive patients with DM, tight control of blood pressure is
of particular importance and intense non-pharmacological and
pharmacological interventions should be implemented to lower
blood pressure to below 130/80 mmHg [15]. In contrast to the
clear recommendations and guidelines of medical scientific
societies, there is increasing evidence for a disparity between
scientifically grounded treatment targets and the actual imple-
mentation of guidelines by physicians in Germany [16].
Our analysis compares the results of the DETECT study with
55,518 participants in 2003 for the estimated prevalence rates
using different definitions for diagnosis of hypertension and
compares treatment and control rates with the results of the
Hypertension and Diabetes Risk Screening and Awareness Study
(HYDRA) study [3] with 45,125 participants in 2001 and also
comparisons with other German and international studies are
made. At the same time the determinants of pharmacotherapy and
adequate blood pressure control including among high-risk
patients with comorbidities are examined. We used the criteria
of the JNC 7 guidelines for the classification of the severity of
hypertension: normal BP for a systolic BP,120 mmHg and a
diastolic BP,80 mmHg; prehypertension for a systolic BP
between 120 to 139 mmHg and/or diastolic BP between 80 to
89 mmHg; stage 1 hypertension for a systolic BP between 140 and
159 and/or a diastolic BP between 99 and 90 mmHg; stage 2
hypertension for a systolic BP$160 mmHg and/or a diastolic
BP$100 mmHg. These categories are almost identical to those
suggested by the European Society of Hypertension/European
Society for Cardiology (ESH/ESC) [12]. If the systolic and
diastolic BP would have led to a different categorisation for
hypertension the higher category was chosen.
Methods
DETECT (Diabetes Cardiovascular Risk-Evaluation: Targets
and Essential Data for Commitment of Treatment) was initiated
to estimate the prevalence and comorbidity patterns of primary
care patients and to evaluate new strategies for the prevention and
early detection of chronic diseases [17,18]. The DETECT study
was designed to evaluate the impact of characteristics of the
patient and the physician on diagnosis, treatment and control of
hypertension. It is a large-scale, cross-sectional study with
longitudinal follow-up of a subcohort and nationally representative
of primary care situation in Germany [3]. Sampling and data
collection for the DETECT study were very similar to the
HYDRA study and based on a nationwide sample of physicians
with primary care functions (medical practitioners, generalists,
general internists). More information about the DETECT study
can be found on http://www.detect-studie.de and about the
HYDRA study on http://www.hydra-studie.de. HYDRA was a
precursor study of DETECT with identical methods of sampling,
design and also assessment of hypertension [19]. All patients
consulting a practice for whatever reason on 16
th or 18
th
September 2003 were included in the DETECT study. The
sampling was based on 1060 regional segments in Germany
(according to the criteria of the Institute for Medical Statistics,
Frankfurt am Main, Germany), 7053 primary care physicians
being randomly selected as a sample from all 64707 physicians
who had been working as primary care physicians in Germany in
2003 [3]. Following a pre-study to determine characteristics of
physicians and settings, the cross-sectional baseline study in the
year 2003 was based on a sample of 55519 unselected adult
patients, who were examined in a total of 3188 nationally
representative primary care offices (73% general practitioners and
27% internists). Participating patients completed a standardized
questionnaire regarding sociodemographic and lifestyle factors.
Physicians completed a standardized questionnaire asking for
information about known or newly diagnosed medical conditions
and an evaluation of the clinical and therapeutic profiles of the
patients. Information about prescribed anti-hypertensive medica-
tion and results of the current examination (e.g. blood lipid levels,
blood pressure measurements according to the JNC 7 report [20])
were also provided by the physician. For the analysis baseline data
of the DETECT study for the year 2003 were used. Age groups
were defined as follows: 18–29, 30–44, 45–59, 60–74 and 75+
years.
Ethics Statement
The DETECT study was approved by the ethics committee of
the Dresden University of Technology (TU Dresden). Written
informed consent was received from all participants.
Diagnostic Conventions
In order to allow a comparison of the DETECT study
specifically with the previous HYDRA study and further related
studies in Germany, this paper applies the methods used and
described in a previous study for the measurement of prevalence of
hypertension [3]. In DETECT, blood pressure measurements
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examination and were done by indirect cuff sphygmomanometry
after a 10-minute of rest in a sitting position according to the
international guidelines [20]. In both studies (HYDRA and
DETECT) blood pressure was only measured once. Prevalence
rates of hypertension were examined using the following
definitions which has also used in the HYDRA study as precursor
study: a) physician’s diagnosis of hypertension as coded in the
clinical appraisal questionnaire (HTNdoc); b) physician’s diagnosis
or the patient’s self-reported diagnosis of hypertension (HTNdoc,-
pat); c) physician’s or patient’s self-reported diagnosis or aB P
measurement with a systolic BP$140 mmHg and/or a diastolic
BP$90 (HTNdoc,pat,bp); d) diagnosis according to the National
Health and Nutrition Examination Survey (HTNNHANES) [21], i.e.
a measured BP$140/90 mmHg or treatment with antihyperten-
sive drugs, irrespective of the doctor’s or patient’s self-reported
diagnosis. For the estimation of the proportion of diagnosed
patients (,140/90 mmHg) we used the HTNNHANES criterion for
defining hypertension [21,22]. These patients were defined as
treated if they received antihypertensive drugs and the following
drug classes were included: ACE inhibitors, AT1-antagonists,
beta-blockers, calcium channel blockers and diuretics. These
patients were defined as controlled if blood pressure was below
140/90 mmHg.
Cardiovascular Comorbidity
The physicians’ questionnaire explicitly asked for the existence
of 28 specified medical diagnoses and also allowed for adding
further diagnoses. CHD, DM and hyperlipidemia were exclusively
defined as physicians’ based diagnoses (newly diagnosed or
previously known) [18]. The physicians’ questionnaire contained
information about previous myocardial infarction and family
history of myocardial infarction.
Cardiovascular Risk Factors
The patients’ questionnaire contained information about
physical activity and smoking status as cardiovascular risk factors.
Physical activity was classified as either more than or equal to 2
hours per week versus physical activity with less than 2 hours per
week on average (e.g. gardening, cycling, walking or other sports).
Smoking status of the participants was defined as use of any
tobacco product in the past 4 weeks and categorized as yes/no.
BMI was categorized into three groups: ,25 kg/m
2 (normal), 25
to ,30 kg/m
2 (overweight) and $30 kg/m
2 (obesity). Waist
circumference (WC) was categorized into the following groups:
#94 cm for males and #80 cm for females as not overweight,
.94 cm and #102 cm for males and .80 cm and #88 cm for
females as pre-obese, .102 cm for males and 88 cm for females as
obese.
Statistical Analyses
DETECT study participants were analyzed with respect to
socio-demographic, comorbidities and cardiovascular lifestyle risk
factors. Gender and age-group specific estimates of prevalence
rates of hypertension were determined applying alternative
definitions of hypertension in unselected primary care patients.
Also the prevalence of hypertension according to JNC 7 categories
was analyzed. Determinants associated with pharmacotherapy and
adequate BP control of hypertension such as socio-demographic
comorbidities and cardiovascular lifestyle risk factors were
evaluated using multiple logistic regression. Education in years
was included in the models as potentially explanatory factor. The
patients were clustered by primary care units and to account for
the clustered structure of the data, robust standard errors were
estimated by the Huber-White Matrix. Data were weighted for
non-response and attrition during the recruitment phase. Cate-
gorical data were presented as absolute frequencies (n) and
weighted percentages (%w), metric variables by weighted mean
and standard deviation. A two-sided alpha-level of 0.05 was
chosen as criterion for statistical significance. All statistical analyses
were conducted using STATA 11.2 (Stat Corp. 2009, College
Station, Texas, USA).
Results
Table 1 presents descriptive statistics for sociodemographic and
baseline variables for the 55,518 participants of the DETECT
study in 2003. The average systolic BP was 131.7 mmHg and
diastolic BP was 79.9 mmHg. Of the participants of the DETECT
study, 12.1% had physician diagnosed DM, 29.5% hyperlipide-
mia, 14.7% CHD and 4.2% previous myocardial infarction.
Physician based diagnosis of hypertension (HTNdoc) was present in
35.5% of all participants (see table 2). The prevalence rate of
physician diagnosed hypertension increased from the youngest age
group (18 to 29 years) to the oldest one (75 years and above) from
2.9% from to 62.6%. Physician’s diagnosis or the patient’s self-
reported diagnosis of hypertension (HTNdoc,pat) showed slightly
higher prevalence rates: 41.8% in all participants, 6.4% in the
youngest age group and 69.5% in the oldest age group. Physician’s
or patient’s self-reported diagnosis or a BP measurement with a
systolic BP$140 mmHg and/or a diastolic BP$90 (HTNdoc,pat,bp)
prevalence rates increased to 55.2% in all participants and were
15.4% and 82.1% in the youngest and oldest age group,
respectively. Prevalence rates for hypertension diagnosis according
to the National Health and Nutrition Examination Survey
(HTNNHANES) were in a similar range as for HTNdoc,pat,bp:
56.0% in all participants, 13.3% in the youngest and 86.8% in the
oldest age group. Comparing the estimated prevalence rates for
HTNdoc, HTNdoc,pat, HTNdoc,pat,bp and HTNNHANES, the largest
differences measured as ratio of 2 estimated prevalence rates were
seen in the youngest age group comparing HTNdoc and
HTNNHANES. The biggest percent difference in absolute number
was present in the oldest age group comparing HTNdoc to
HTNNHANES. Limitations of the DETECT study exist, because
there was only single measurement of blood pressure in a primary
care setting done. Some patients have been excluded from the
study, because of time restrictions of the physician or no clinical
assessment was possible [23]. Several measurements are recom-
mended and prevalence of hypertension is dependent from the
setting and inclusion criteria of patients [18].
The categories of the measured BP values according to the JNC
7 classification are shown in table 3 stratified by age and sex.
14.9% of the participants had normal blood pressure, 44.6%
prehypertension, 28.8% stage 1 hypertension and 11.6% stage 2
hypertension. The prevalence rates of hypertension stages 1 and 2
increased together with age. In participants between age 18 and 29
prevalence rates were 10.2% and 1.8%, in patients above 75 years
of age prevalence rates were 41.2% and 18.7%, respectively. The
mean systolic BP increased continuously with age up to
140.6 mmHg in participants above 75 years of age and diastolic
BP increased up to 81.6 mmHg in the age group 60–74 years, but
decreased to 79.9 mmHg again in the oldest age group.
Diagnosis, Treatment and Control Rates in the DETECT
Study
Across all age groups 61.5% of HTNNHANES cases were
diagnosed (coded in the clinical appraisal) by the physicians. In the
youngest there was the smallest proportion of diagnosed
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of physician diagnosed cases was highest (71.0%). The rates of
HTNNHANES cases, which were diagnosed and also treated by
physicians increased with higher age: 12.1% in the youngest age
group and 65.7% in the oldest age group. Among HTNNHANES
cases the proportion of patients with adequate blood pressure
control was 21.4% across all groups; it was 5.8% in the youngest
and 23.3% in the oldest age group.
Comparison between HYDRA and DETECT Study
The comparison presented in figure 1 reveals that the
proportion of diagnosed patients was lower in the DETECT
study in comparison to the HYDRA study. These changes are
consistent, and are significant (p,0.05) in all age groups above age
30 for men and women. The comparison between these studies
shows also indications of, albeit small, improvements in rates of
treated and controlled hypertension. The changes are consistent,
although not significant in all gender and age group comparisons.
Significant improvements (p,0.05) in the rates of treatment were
found in females 30–44 years of age and in males 30–44 and 45–
59 years of age. Rates of antihypertensive drug therapy decreased
significantly in male patients aged 75 years and older. Adequate
BP control was significantly more common in older female
patients (age group 60+ years).
Factors Associated with Pharmacotherapy
Table 4 shows factors associated with pharmacotherapy for
hypertension. Patients in the oldest age group were approximately
tenfold more likely to take antihypertensive drugs (OR 10.58,
95%-CI 8.36–13.39). Further factors associated with receiving
antihypertensive medication in NHANES based cases were female
sex (OR 1.18, 95%-CI 1.10–1.27), BMI above 30 kg/m
2 (OR
1.72, 95%-CI 1.57–1.89), a history of CHD (OR 4.64, 95%-CI
3.92–5.50), a physician based diagnosis of hyperlipidemia (OR
1.66, 95%-CI 1.54–1.79), DM (OR 1.98, 95%-CI 1.79–2.19) or
previous myocardial infarction (OR 2.27, 95%-CI 1.60–3.21). An
alternative specification with waist circumference (reference
category: not overweight) instead of BMI as a measure of
cardiovascular risk gave very similar results. Smoking was
negatively associated with receiving antihypertensive medication
(OR 0.79, 95%-CI 0.72–0.86).
Table 1. Sample characteristics of DETECT study participants.
Total Male Female
(N=55,518) (N=22,679) (N=32,839)
N% w N% w N% w
Age (mean/sd) 53.8/17.4 54.5/16.8 53.3/17.8
18–29 years 6,031 11 2,249 9.9 3,782 11.7
30–44 years 11,525 21 4,328 19.5 7,197 22.1
45–59 years 13,555 24.3 5,599 24.5 7,956 24.1
60–74 years 17,934 31.9 8,087 35.3 9,847 29.5
75+ years 6,473 11.9 2,416 10.9 4,057 12.6
Systolic blood pressure, (mean/sd) 131.7/18.4 133.8/17.3 130.3/19.0
Diastolic blood pressure, (mean/sd) 79.9/9.9 80.8/9.8 79.2/10.0
Years of schooling, (mean/sd) 10.1/2.1 10.2/2.2 10.0/2.0
BMI (mean/sd) 26.8/5.3 27.3/4.7 26.5/5.6
,25 kg/m
2 21,520 40.2 7,037 32.1 14,483 45.8
25–29.9 kg/m
2 20,383 37.3 10,201 45.8 10,182 31.5
30+ kg/m
2 12,491 22.5 4,986 22.2 7,505 22.7
WC (mean/sd) 93.8/15.6 99.8/13.8 89.7/15.4
#94 cm (male) #80 cm (female) 15,595 31.9 6,667 33.6 8,928 30.7
.94 cm–#102 cm (male) .80 cm–#88 cm (female) 10,729 21.9 5,245 26.4 5,484 18.9
.102 cm (male) .88 cm (female) 22,593 46.2 7,930 40 14,663 50.4
Current smoker 13,504 26.1 6,186 29.2 7,318 24
Physical activity ,2 hours/week 16,265 34.3 5,902 30.3 10,363 37.2
Comorbidities
CHD 8,465 14.7 4,127 17.6 4,338 12.8
Hyperlipidemia 16,178 29.5 7,311 32.4 8,867 27.5
Diabetes mellitus 6,895 12.1 3,969 17.2 2,926 8.6
Myocardial infarction 2,326 4.2 1,649 7.3 677 2.1
N=55,518, %w=weighted percentages; BMI=body mass index in kg/m2.
Number of valid observations: Blood pressure n=53,337 (96.1%); Years of schooling n=53,406 (96.2%); Body mass index.
n=54,393 (98.0%); Waist circumference n=48,918 (88.1%); Smoking status n=52,589 (94.7%); Physical activity n=48,249 (86.9%).
doi:10.1371/journal.pone.0052229.t001
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no
HTNdoc HTNdoc
no
HTNdoc/Pat HTNdoc/Pat
no
HTNdoc/Pat/bp HTNdoc/Pat/bp
no
HTNNNANES
{ HTNNHANES
{
N N %w N N %w N N %w N N %w
Total Total 35,354 20,164 35.5 31,858 23,660 41.8 24,569 30,949 55.2 23,148 30,189 56.0
Female 21,539 11,300 33.6 19,667 13,172 39.3 15,701 17,138 51.6 14,969 16,620 52.0
Male 13,815 8,864 38.3 12,191 10,488 45.5 8,868 13,811 60.4 8,179 13,569 61.9
18–29
years
Total 5,854 177 2.9 5,634 397 6.4 5,099 932 15.4 5,017 771 13.3
Female 3,693 89 2.3 3,586 196 5.0 3,324 458 12.2 3,258 372 10.3
Male 2,161 88 4.0 2,048 201 8.8 1,775 474 20.8 1,759 399 18.3
30–44
years
Total 10,291 1,234 10.1 9,726 1,799 14.9 8,192 3,333 28.3 8,014 3,056 27.1
Female 6,551 646 8.5 6,250 947 12.6 5,499 1,698 23.1 5,369 1,558 22.1
Male 3,740 588 12.7 3,476 852 18.8 2,693 1,635 37.0 2,645 1,498 35.5
45–59
years
Total 9,068 4,487 32.0 8,113 5,442 39.1 5,992 7,563 55.1 5,744 7,291 55.1
Female 5,559 2,397 29.0 5,062 2,894 35.3 3,891 4,065 50.3 3,754 3,908 50.2
Male 3,509 2,090 36.3 3,051 2,548 44.5 2,101 3,498 61.8 1,990 3,383 62.2
60–74
years
Total 7,778 10,156 56.0 6,460 11,474 63.5 4,149 13,785 76.7 3,569 13,664 79.0
Female 4,294 5,553 55.7 3,590 6,257 63.0 2,321 7,526 76.2 2,104 7,375 77.5
Male 3,484 4,603 56.2 2,870 5,217 64.0 1,828 6,259 77.3 1,465 6,289 80.9
$75
years
Total 2,363 4,110 62.6 1,925 4,548 69.5 1,137 5,336 82.1 804 5,407 86.8
Female 1,442 2,615 63.3 1,179 2,878 70.0 666 3,391 83.1 484 3,407 87.1
Male 921 1,495 61.2 746 1,670 68.8 471 1,945 80.5 320 2,000 86.1
N=55,518,{ N=53,337 patientswithvalid bloodpressure assessment; %w=weighted percentages HTNdoc: doctor’s diagnosis;HTNdoc/pat:doctor’s orpatient’s diagnosis;
HTNdoc/pat/bp: doctor’s or patient’s diagnosis or blood pressure 140/90 mmHg; HTNHANES: blood pressure .140/90 mmHg or receiving antihypertensive therapy.
doi:10.1371/journal.pone.0052229.t002
Table 3. Prevalence of JNC 7 Blood Pressure Categories.
BP,120/80 mmHg BP 120–139/80–89 mmHg BP 140–159/90–99 mmHg BP$160/100 mmHg
N %w N %w N %w N %w
Total{ Total 7,839 14.9 23,890 44.6 15,489 28.8 6,119 11.6
Female 5,729 18.5 13,894 43.8 8,486 26.6 3,480 11.2
Male 2,110 9.8 9,996 45.8 7,003 32.1 2,639 12.3
18–29 years Total 2,114 36.8 2,982 51.3 584 10.2 108 1.8
Female 1,608 44.7 1,699 46.2 284 8.0 39 1.0
Male 506 23.1 1,283 59.9 300 13.8 69 3.2
30–44 years Total 2,681 24.6 5,882 52.9 1,935 17.3 572 5.2
Female 2,155 31.5 3,539 50.9 975 13.9 258 3.7
Male 526 13.1 2,343 56.3 960 22.9 314 7.7
45–59 years Total 1,630 12.8 6,089 46.6 3,880 29.5 1,436 11.1
Female 1,216 16.2 3,623 47.2 2,091 27.0 732 9.6
Male 414 7.9 2,466 45.9 1,789 33.0 704 13.2
60–74 years Total 1,081 6.3 6,768 39.1 6,519 37.7 2,865 17.0
Female 583 6.2 3,723 39.2 3,518 36.8 1,655 17.8
Male 498 6.5 3,045 38.9 3,001 38.8 1,210 15.9
$75 years Total 333 5.4 2,169 34.8 2,571 41.2 1,138 18.7
Female 167 4.3 1,310 33.6 1,618 41.1 796 21.0
Male 166 7.2 859 36.7 953 41.3 342 14.8
{N=53,337 patients with valid blood pressure assessment; %w=weighted percentages; BP=blood pressure.
doi:10.1371/journal.pone.0052229.t003
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In HTNdoc cases, the factors associated with adequate blood
pressure control (less than 140/90 mmHg) were female sex (OR
1.16, 95%-CI 1.07–1.25), the presence of CHD (OR 1.25, 95%-
CI 1.13–1.39), previous myocardial infarction (OR 1.76, 95%-CI
1.50–2.05) and antihypertensive medication (OR 1.41, 95%-CI
1.23–1.61) (table 5). With increasing age the likelihood of adequate
blood pressure control was reduced (OR 0.57, 95%-CI 0.39–0.82
for the highest age group) and also for a BMI above 30 kg/m
2
(OR 0.67, 95%-CI 0.61–0.74). An alternative specification with
waist circumference (reference category: not overweight) instead of
BMI as a measure of cardiovascular risk gave also very similar
results in this regression. Comorbidities (hyperlipidemia, DM and
lifestyle factors) such as physical activity and smoking status) had
no effect on blood pressure control.
Figure 1. Diagnosis, treatment and control rates among NHANES hypertension cases in DETECT and HYDRA study. Comparison
between DETECT study (N=30189) and HYDRA study (N=22744) for diagnosis, treatment and control rates. Diagnosed=diagnosed by physician
among NHANES cases; diagnosed+treated=diagnosed by physician and treated by antihypertensive drugs among NHANES cases;
diagnosed+treated+controlled=diagnosed by physician, treated by antihypertensive drugs and blood pressure ,140/90 mmHg among NHANES
cases. A comparison between both studies reveals that the proportion of diagnosed patients among NHANES hypertension cases was lower in the
first study for all age groups above age 30 for men and women (p,0.05). Small (significant) improvements in rates of diagnosed and treated
hypertension were found in females 30–44 years of age and in males 30–44 and 45–59 years of age (p,0.05). Small (significant) improvements in
rates of diagnosed, treated and controlled hypertension were found in females 60–64 years of age and in males 30–44 and 45–59 years of age
(p,0.05).
doi:10.1371/journal.pone.0052229.g001
Table 4. Determinants of pharmacotherapy among NHANES hypertension cases.
Antihypertensive treatment (N=21,323)
All With treatment Unadjusted Adjusted
{
N N %w OR
# 95% CI OR
{ 95% CI
Male gender 12,941 9,464 72.3 (reference) (reference)
Female gender 15,876 11,859 73.9 1.08* 1.02–1.14 1.18* 1.10–1.27
Age in years
18–29 682 146 20 (reference) (reference)
30–44 2,811 1,194 40.8 2.75* 2.24–3.39 2.08* 1.67–2.59
45–59 6,903 4,604 65.6 7.62* 6.24–9.30 4.57* 3.70–5.65
60–74 13,202 10,827 81.4 17.57* 14.42–21.40 8.19* 6.61–10.16
$75 5,219 4,552 86.5 25.68* 20.81–31.68 10.58* 8.36–13.39
Years of schooling, (mean/sd)
{ 9.4/2.0 0.87* 0.86–0.88 0.98 0.97–1.00
BMI
,25 kg/m
2 7,095 4,745 66.3 (reference) (reference)
25–29.9 kg/m
2 12,169 9,008 73.4 1.41* 1.32–1.51 1.24* 1.14–1.35
30+ kg/m
2 9,186 7,283 78.2 1.82* 1.69–1.96 1.72* 1.57–1.89
Current non-smoker 22,809 17,536 76.1 (reference) (reference)
Current smoker 4,912 2,952 59.6 0.46* 0.43–0.50 0.79* 0.72–0.86
Physical activity $2 hours/week 16,422 12,025 72.2 (reference) (reference)
Physical activity ,2 hours/week 7,903 5,660 70.9 0.94* 0.88–1.00 1.02 0.94–1.09
Comorbidities
no CHD 22,829 15,639 67.6 (reference) (reference)
CHD 5,988 5,684 94.9 8.83* 7.80–9.99 4.64* 3.92–5.50
no Hyperlipidemia 16,825 11,274 65.8 (reference) (reference)
Hyperlipidemia 11,992 10,049 83.2 2.56* 2.41–2.72 1.66* 1.54–1.79
no Diabetes mellitus 21,814 15,144 68.6 (reference) (reference)
Diabetes mellitus 7,003 6,179 87.8 3.28* 3.02–3.56 1.98* 1.79–2.19
no Myocardial infarction 26,719 19,287 71.3 (reference) (reference)
Myocardial infarction 2,098 2,036 96.9 12.66* 9.73–16.47 2.27* 1.60–3.21
N=30,189; %w=weighted percentages; OR=Odds Ratio estimated by logistic regression; 95% CI=95% confidence interval.
#unadjusted OR;
{adjusted OR from multivariate analyses;
*significant on 5% level.
{OR for increase of 1 year.
doi:10.1371/journal.pone.0052229.t004
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Prevalence of hypertension was dependent on the definition
used, and was lowest for HTNdoc and highest for HTNNHANES.
Comparison of diagnosis and treatment rates and of the
proportion with adequate control among patients in the DETECT
and HYDRA studies showed only a small improvement in
treatment and control rates between 2001 and 2003 and a slight
decline in diagnosis rates. The comorbidities of CHD and previous
myocardial infarction were associated with pharmacotherapy and
adequate blood pressure control, whereas for patients with other
comorbidities such as DM and hyperlipidemia control was less
likely.
Prevalence of Hypertension
Different definitions of hypertension revealed remarkable
differences in prevalence rates. The prevalence rates were lowest
for HTNdoc and HTNdoc,pat and highest for HTNNHANES and
HTNdoc,pat,bp (56.0% and 55.2%, respectively). This shows that a
considerable fraction of people with hypertension had not been
diagnosed by physicians. As a consequence treatment and control
rates of HTNNHANES based cases are lower in comparison with
treatment and control rates based on physician based diagnoses.
Only one study (HYDRA) which is similar to the current one
uses the same definitions for hypertension and for the calculation
of the prevalence, diagnosis, treatment and control of hypertension
[3]. Prevalence rates of hypertension in this study were slightly
higher over all groups for HTNdoc with 38.8% and slightly lower
for HTNNHANES with 50.4%. HTNdoc,pat with 39.5% and
HTNdoc,pat,bp with 52.4% were almost in the same range as in
the DETECT study. The total prevalence of hypertension based
only on physician’s assigned diagnosis should be considered with
caution and these results were found in both studies. The degree of
Table 5. Determinants of adequate blood pressure control among physician diagnosed hypertension cases.
Adequate blood pressure control (N=6989)
All Adequate control Unadjusted Adjusted
{
N N %w OR
# 95% CI OR
{ 95% CI
Male gender 8,570 3,085 35.5 (reference) (reference)
Female gender 10,959 3,904 35.3 0.99 0.93–1.05 1.16* 1.07–1.25
Age in years
18–29 168 77 45.3 (reference) (reference)
30–44 1,187 465 38.7 0.76 0.54–1.07 0.88 0.61–1.28
45–59 4,337 1,619 36.8 0.71* 0.51–0.98 0.76 0.53–1.08
60–74 9,841 3,491 35.2 0.66* 0.48–0.90 0.66* 0.47–0.95
$75 3,996 1,337 33 0.60* 0.43–0.83 0.57* 0.39–0.82
Years of schooling, (mean/sd)
{ 9.4/2.0 1.03* 1.01–1.04 1.01 1.00–1.03
BMI
,25 kg/m
2 4,035 1,639 40.6 (reference) (reference)
25–29.9 kg/m
2 8,200 3,027 36.3 0.83* 0.77–0.90 0.85* 0.77–0.93
30+ kg/m
2 7,019 2,237 31.4 0.67* 0.61–0.73 0.64* 0.57–0.70
Current non-smoker 15,881 5,689 35.3 (reference) (reference)
Current smoker 2,752 1,005 36.5 1.05 0.96–1.15 0.98 0.88–1.09
Physical activity $2 hours/week 10,883 4,017 36.5 (reference) (reference)
Physical activity ,2 hours/week 5,271 1,843 34.4 0.91* 0.85–0.98 0.94 0.86–1.01
Comorbidities
no CHD 14,821 5,037 33.4 (reference) (reference)
CHD 4,708 1,952 41.7 1.42* 1.32–1.53 1.25* 1.13–1.39
no Hyperlipidemia 10,035 3,572 35.1 (reference) (reference)
Hyperlipidemia 9,494 3,417 35.7 1.03 0.97–1.10 0.97 0.90–1.05
no Diabetes mellitus 13,757 4,969 35.7 (reference) (reference)
Diabetes mellitus 5,772 2,020 34.7 0.96 0.89–1.02 0.99 0.91–1.08
no Myocardial infarction 18,000 6,242 34.2 (reference) (reference)
Myocardial infarction 1,529 747 48.6 1.82* 1.63–2.03 1.76* 1.50–2.05
no Antihypertensive treatment 1,533 458 29.4 (reference) (reference)
Antihypertensive treatment 17,236 6,296 36.2 1.36* 1.21–1.53 1.41* 1.23–1.61
N=20,164, %w=weighted percentages; OR=Odds Ratio estimated by logistic regression; 95% CI=95% confidence interval.
#unadjusted OR;
{adjusted OR from multivariate analyses;
*significant on 5% level.
{OR for increase of 1 year.
doi:10.1371/journal.pone.0052229.t005
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is still notable in the older age groups. Our results for the
prevalence rate of hypertension are in accordance with a
population-based study for Germany (German National Health
Interview and Examination Survey 1998) with prevalence rates
only slightly lower if applying NHANES definition criteria in this
study (53.5% for men and 43.6% for women) [2]. These results
suggest that a substantial proportion of people in primary care
with hypertension according to NHANES definition criteria are
not diagnosed as hypertensive by physicians in Germany.
In a cohort study with original and offspring cohort members of
the Framingham Heart Study, the prevalence rate of hypertension
according to the NHANES criteria was 27.3% in participants
younger than 60 years of age, 63.0% in participants between 60
and 79 years of age and 74.0% in participants above 80 years of
age [24]. These age-specific prevalence rates are lower than for the
DETECT study (79.0% for participants between age 60–74 and
86.8% for participants above age 75). One study identified
international differences in prevalence, treatment and control rates
of hypertension in six different countries (France, Germany, Italy,
Spain, UK, US) and used the CardioMonitor Surveys for the year
2004 [25]. In that study, the prevalence of hypertension was
determined according to the physician’s diagnosis, which is
identical to our HTNdoc definition. Between these six countries
there was a range of prevalence rates of hypertension between
78% in UK and 90% in Italy, the prevalence in Germany being
86%. The surprisingly high prevalence rates of hypertension in
comparison to the DETECT and HYDRA study can be explained
partly by the fact, that these surveys were visit-based and not
population-based. Physician sampling was based on a quota
criterion – each physician had a minimum of 15 patients per week
with a cardiovascular disease to be included in the respective
countries. Sicker patients were oversampled and as a consequence
a selection problem with a high proportion of patients with
comorbidities existed. The high prevalence rates for hyperlipide-
mia with 49% and for DM with 29% in the German
CardioMonitor survey are in accordance with this interpretation.
The prevalence rates in the DETECT study were much lower for
hyperlipidemia with 29.5% and for DM with 12.1%.
Diagnosis, Treatment and Control Rates of Hypertension
On the one hand, there is a decrease in the proportion of
patients diagnosed by physicians in the DETECT study in
comparison to the HYDRA study. On the other hand, age-
specific treatment and control rates were slightly higher. This
means that, despite continuous efforts to improve management of
hypertension which have included the publication of the HYDRA
results, intense continuous medical education (CME) and intensive
training programs, there is only a slight improvement of treatment
and control and even a decline in the diagnosis rate.
The WHO-Monica-Augsburg study, conducted in 1994/95,
has also reported diagnosis, treatment and control rates which
have been in a lower range [4]. In contrast to our study, diagnosis
of hypertension was defined as reporting a prior diagnosis of
hypertension by the participants instead of using the physicians’
diagnosis. Diagnosis rate was about 60% for women and 50% for
men in 1994/95 and similar to own results in the DETECT study.
In comparison with the DETECT study, treatment rates were
lower (23% in men and 33% in women) and also control rates
were lower (7% in men and 13% in women). Further German
studies, for example, the German National Health Interview and
Examination Survey in 1998 [16], have the limitation of using
another definition for diagnosis of hypertension (awareness) or the
study has only been conducted in certain parts of Germany, as the
Study of Health in Pomerania (SHIP) [26].
Higher control rates of hypertension were reported in the USA
compared to those in Germany [22,27]. In the Framingham Heart
Study treatment rates were 68.9% across the age groups [24].
Overall, the rates of control were 32.4% in participants with
hypertension and 47.0% in treated participants. The estimated
sex-specific rate of control was 38% for women and 23% for men.
Factors Associated with Pharmacotherapy
DETECT also allowed for the evaluation of the impact of
patient characteristics as determinants of pharmacotherapy.
Patients with higher age and BMI and comorbidities such as
CHD, DM, myocardial infarction, hyperlipidemia showed a
higher probability of receiving pharmacotherapy, in agreement
with guidelines. These results are partially different from those of
the ESTHER study, which is a cohort study conducted in a
primary care setting in the German Federal State of Saarland [28].
The analyzed sample were hypertensive patients with DM. Similar
results for predictors of receiving pharmacotherapy as in the
DETECT study were obtained for higher age and BMI, female
sex, CHD and current non-smoking. Physical activity and
hyperlipidemia had no influence which is in contrast to the
DETECT results. A study in the USA of members of the National
Health and Human Services Employees Union showed a higher
likelihood of receiving pharmacotherapy in participants with a
higher age and BMI than in the DETECT and ESTHER study
[29]. Sex had, in contrast to the German studies, no influence.
Factors Associated with Blood Pressure Control
In the DETECT study female sex, a lower BMI, CHD, previous
myocardial infarction and antihypertensive medication were
associated with adequate blood pressure control. This is in
accordance with guideline recommendations that in patients with
comorbidities such as CHD or previous myocardial infarction
blood pressure control is of high importance. These results are in
contrast to the results of the ESTHER study. In this study the only
significant negative predictor of an adequate blood pressure in
patients with both DM and hypertension was higher age. The
difference between DETECT and ESTHER could be explained
first by the fact that hypertensive patients with DM are a special
subpopulation of hypertensive patients, and second, by choosing a
different cut-off point for adequate blood pressure control with a
systolic BP of 130 mmHg and a diastolic BP of 85 mmHg in the
ESTHER study.
Results for the prediction of adequate blood pressure control in
the DETECT study are also in part in agreement with data for
hypertensive patients with DM treated in primary care clinics in
the USA [30]. In a retrospective study a higher age was a
significant negative predictor for adequate blood pressure control.
A history of CHD and also at least one annual visit to a
subspecialist had a significant positive influence. In contrast to the
results of the DETECT study, no influence of BMI and gender
were found and also smoking and physical activity had no
influence. Two further studies in the USA estimating control rates
had differing results. In the first only female sex and the number of
antihypertensive drugs days had a positive significant influence on
control of hypertension, whereas higher age, race and a higher
BMI played no significant role [29]. The National Health and
Nutrition Examination Survey (NHANES) showed that an age of
at least 65 years, male sex, not having visited a physician during
the last 12 months had a negative predictive value for an adequate
blood pressure control in patients aware of their hypertension [31].
Education, family income and current smoking status had no
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all these studies with the DETECT study shows that a comorbidity
such as CHD leads to a higher probability of adequate control,
although other potentially remediable factors such as smoking
status or physical activity show no association.
As a first limitation of the DETECT study it should be
mentioned that blood pressure measurement was only done once,
and not repeatedly, under primary care conditions. For a high
degree of certainty about diagnosis of hypertension different
methods and using the average of several measurements are
recommended [23]. A single measurement could increase the
prevalence of hypertension according to the HTNNHANES
definition, because the phenomenon of white coat hypertension
could subsequently lead to an underestimation of treatment rates
and blood pressure control. In the original study which defined the
HTNNHANES criteria for measuring prevalence in the US, two sets
of measurements during two different visits had been taken [21]. A
second limitation of our analysis is the coding of medical diagnoses
DM, CHD and hyperlipidemia: it has been based only on a
clinical assessment and has not been validated by objective criteria.
A third limitation is that a central laboratory was only used in a
subset of patients while in other patients values were taken from
the patients records. A fourth limitation is that the time interval
between the acquisition of laboratory values and completing the
questionnaire was not comparable for all patients, because it was
not fixed for all patients. A further limitation was that for
estimation of treatment rates of hypertension only pharmacolog-
ical interventions were considered and no non-pharmacological
interventions were taken into account, so that the treatment rates
would be higher if non-pharmacological interventions could also
have been considered. Estimation of control rates would have been
lower if recommended BP values in the guidelines for patients with
comorbidities including hyperlipidemia or DM would have been
considered.
Conclusions
Differing definitions of hypertension exist and as a consequence
the prevalence rates of hypertension vary accordingly in the
DETECT and HYDRA studies. A comparison of the rates of
treated and controlled hypertension in the DETECT study with
the HYDRA study show indications of small improvements in
proportions of patients adequately controlled, although levels of
control remain low. With respect to proportions of people
diagnosed, there is even a decline. Hypertensive patients with risk
factors such as obesity and associated comorbidities such as CHD,
hyperlipidemia and DM were more likely to receive antihyper-
tensive drugs in accordance with guidelines. A higher rate of
adequate blood pressure control was achieved in patients with
obesity and CHD, but not those with DM or hyperlipidemia.
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